Market Access Lessons For Cell And Gene Therapies In Germany
Companies Can Learn From Bluebird Bio’s Failed Zynteglo Pricing Deal
Lawyer and industry expert Alexander Natz sets out some important dos and don’ts for securing a successful launch of an advanced therapy in Germany.
You may also be interested in...
Dutch HTA Body Hits Out At Bluebird’s Zynteglo Pricing
The Netherlands calls for multi-country price negotiations for gene therapy Zynteglo.
Safety Thumbs Up For Zynteglo Prompts Bluebird To Lift Marketing Suspension
No evidence has been found linking the viral vector in bluebird’s gene therapy for β-thalassemia to blood cancer, the European Medicines Agency says.
Germany To Tackle Cell And Gene Therapy Funding Barriers
If approved, new legislation would allow hospitals to apply for funding for ATMPs before marketing authorization.